Familial Cancer

, Volume 16, Issue 3, pp 339–349 | Cite as

The association between prognosis of breast cancer and first-degree family history of breast or ovarian cancer: a systematic review and meta-analysis

  • Jun-Long Song
  • Chuang Chen
  • Jing-Ping Yuan
  • Sheng-Rong SunEmail author


Whether a positive family history of breast cancer or ovarian cancer (FHBOC) would affect the prognosis of breast cancer is still up for debate and further study. This meta-analysis was performed to clarify this issue. We reviewed two databases (PubMed and CNKI) for research articles published at any time from the inception of these databases to April 1, 2016 for articles detecting the impact of FHBOC on the prognosis of breast cancer. A meta-analysis was conducted to generated combined hazard ratios (HR) with 95% confidence intervals (CI) for overall survival (OS) and breast cancer-specific survival (BCSS). Eighteen studies were included in our qualitative analysis, with 15 studies ultimately part of the quantitative analysis. The pooled results demonstrated that a positive FHBOC was associated with better OS (0.89, 95% CI 0.83–0.95) and BCSS (0.90, 95% CI 0.82–0.99). In subgroup analyses, several subgroups (maximally adjusted studies, population based studies, high quality studies, family history of breast cancer, studies from Europe, studies from Asia, 1 affected relative, or tumor size > 2 cm), a positive first-degree FHBOC was associated with better prognosis of breast cancer. Notably, for those patients who underwent breast-conserving surgery, first-degree FHBOC was not a risk factor for OS (HR 1.08, 95% CI 0.53–2.21). Our meta-analysis demonstrated that a first-degree FHBOC was associated with better OS and BCSS in patients with breast cancer. These findings support that clinical management should not differ between women with and without FHBOC.


Breast cancer Family history Prognosis Systemic review 



This research was supported by the grants from the National Science Foundation of China (No. 81471781 and 81230031), the National Key Scientific Instrument and Equipment Development Project (20133655893), the Natural Science Foundation of Hubei Province, China (2014CKB509 and 2013CFB374).

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.


  1. 1.
    Slattery ML, Kerber RA (1993) A comprehensive evaluation of family history and breast cancer risk. The Utah Population Database. JAMA 270:1563–1568PubMedCrossRefGoogle Scholar
  2. 2.
    Pharoah PD, Day NE, Duffy S et al (1997) Family history and the risk of breast cancer: a systematic review and meta-analysis. Int J Cancer 71:800–809PubMedCrossRefGoogle Scholar
  3. 3.
    Stratton MR, Rahman N (2008) The emerging landscape of breast cancer susceptibility. Nat Genet 40:17–22PubMedCrossRefGoogle Scholar
  4. 4.
    Hemminki K, Ji J, Forsti A (2007) Risks for familial and contralateral breast cancer interact multiplicatively and cause a high risk. Cancer Res 67:868–870PubMedCrossRefGoogle Scholar
  5. 5.
    Shahedi K, Emanuelsson M, Wiklund F, Gronberg H (2006) High risk of contralateral breast carcinoma in women with hereditary/familial non-BRCA1/BRCA2 breast carcinoma. Cancer 106:1237–1242PubMedCrossRefGoogle Scholar
  6. 6.
    Malone KE, Daling JR, Weiss NS et al (1996) Family history and survival of young women with invasive breast carcinoma. Cancer 78:1417–1425PubMedCrossRefGoogle Scholar
  7. 7.
    Malone KE, Daling JR, Doody DR et al (2011) Family history of breast cancer in relation to tumor characteristics and mortality in a population-based study of young women with invasive breast cancer. Cancer Epidemiol Biomark Prev 20:2560–2571CrossRefGoogle Scholar
  8. 8.
    Gonzalez-Angulo AM, Broglio K, Kau SW et al (2005) Women age < or = 35 years with primary breast carcinoma: disease features at presentation. Cancer 103:2466–2472PubMedCrossRefGoogle Scholar
  9. 9.
    Omar MA, Motala AA, Seedat MA and Pirie F, (1996) The significance of a positive family history in South African Indians with non-insulin-dependent diabetes (NIDDM). Diabetes Res Clin Pract 34:S13–S16PubMedCrossRefGoogle Scholar
  10. 10.
    Russo A, Herd-Smith A, Gestri D et al (2002) Does family history influence survival in breast cancer cases? Int J Cancer 99:427–430PubMedCrossRefGoogle Scholar
  11. 11.
    Seynaeve C, Verhoog LC, van de Bosch LM et al (2004) Ipsilateral breast tumour recurrence in hereditary breast cancer following breast-conserving therapy. Eur J Cancer 40:1150–1158PubMedCrossRefGoogle Scholar
  12. 12.
    Thalib L, Wedren S, Granath F et al (2004) Breast cancer prognosis in relation to family history of breast and ovarian cancer. Br J Cancer 90:1378–1381PubMedPubMedCentralCrossRefGoogle Scholar
  13. 13.
    Moher D, Liberati A, Tetzlaff J, Altman DG (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol 62:1006–1012PubMedCrossRefGoogle Scholar
  14. 14.
    Deeks JJ, Dinnes J, D’Amico R et al (2003) Evaluating non-randomised intervention studies. Health Technol Assess 7:1–173CrossRefGoogle Scholar
  15. 15.
    Tierney JF, Stewart LA, Ghersi D et al (2007) Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 8:16PubMedPubMedCentralCrossRefGoogle Scholar
  16. 16.
    Higgins JP, Thompson SG (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21:1539–1558PubMedCrossRefGoogle Scholar
  17. 17.
    Egger M, Davey SG, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315:629–634PubMedPubMedCentralCrossRefGoogle Scholar
  18. 18.
    Begg CB, Mazumdar M (1994) Operating characteristics of a rank correlation test for publication bias. Biometrics 50:1088–1101PubMedCrossRefGoogle Scholar
  19. 19.
    Vlastos G, Mirza NQ, Meric F et al (2002) Breast-conservation therapy in early-stage breast cancer patients with a positive family history. Ann Surg Oncol 9:912–919PubMedCrossRefGoogle Scholar
  20. 20.
    Turkoz FP, Solak M, Aksoy S et al (2012) Association between family history and clinicopathologic characteristics in 1987 breast cancer patients: single institution experience from Turkey. J BUON 17:649–657PubMedGoogle Scholar
  21. 21.
    Slattery ML, Berry TD, Kerber RA (1993) Is survival among women diagnosed with breast cancer influenced by family history of breast cancer? Epidemiology 4:543–548PubMedCrossRefGoogle Scholar
  22. 22.
    Schouten LJ, Hupperets PS, Jager JJ et al (1997) Prognostic significance of etiological risk factors in early breast cancer. Breast Cancer Res Treat 43:217–223PubMedCrossRefGoogle Scholar
  23. 23.
    Melvin JC, Wulaningsih W and Hana Z et al., (2016) Family history of breast cancer and its association with disease severity and mortality. Cancer Med 5:942–49PubMedPubMedCentralCrossRefGoogle Scholar
  24. 24.
    Chen LM, Mundt AJ, Powers C, Halpern HJ, Weichselbaum RR (1996) Significance of family history in breast cancer treated with breast conservation therapy. Breast J 2:238–245CrossRefGoogle Scholar
  25. 25.
    Kinoshita T, Fukutomi T, Iwamoto E, Akashi-Tanaka S (2004) Prognosis of breast cancer patients with familial history classified according to their menopausal status. Breast J 10:218–222PubMedCrossRefGoogle Scholar
  26. 26.
    Kharazmi E, Forsti A, Sundquist K, Hemminki K (2016) Survival in familial and non-familial breast cancer by age and stage at diagnosis. Eur J Cancer 52:10–18PubMedCrossRefGoogle Scholar
  27. 27.
    Jobsen JJ, van der Palen J, Brinkhuis M et al (2016) Long-term effects of first degree family history of breast cancer in young women: Recurrences and bilateral breast cancer. Acta Oncol 55:449–454PubMedCrossRefGoogle Scholar
  28. 28.
    Harris EE, Schultz DJ, Peters CA, Solin LJ (2000) Relationship of family history and outcome after breast conservation therapy in women with ductal carcinoma in situ of the breast. Int J Radiat Oncol Biol Phys 48:933–941PubMedCrossRefGoogle Scholar
  29. 29.
    Chang ET, Milne RL, Phillips KA et al (2009) Family history of breast cancer and all-cause mortality after breast cancer diagnosis in the breast cancer family registry. Breast Cancer Res Treat 117:167–176PubMedCrossRefGoogle Scholar
  30. 30.
    Chabner E, Nixon A, Gelman R et al (1998) Family history and treatment outcome in young women after breast-conserving surgery and radiation therapy for early-stage breast cancer. J Clin Oncol 16:2045–2051PubMedCrossRefGoogle Scholar
  31. 31.
    Cao AY, He M, DI GH et al (2011) Influence of a family history of breast and/or ovarian cancer on breast cancer outcomes. Exp Ther Med 2: 917–23PubMedPubMedCentralGoogle Scholar
  32. 32.
    Yuan ZY, Wang SS, Zhu MQ et al (2008) [Clinical characteristics and prognosis of different subtypes of breast cancer]. Zhonghua Zhong Liu Za Zhi 30:456–61Google Scholar
  33. 33.
    Mohammed SN, Smith P, Hodgson SV et al (1998) Family history and survival in premenopausal breast cancer. Br J Cancer 77:2252–2256PubMedPubMedCentralCrossRefGoogle Scholar
  34. 34.
    Albano WA, Recabaren JA, Lynch HT et al (1982) Natural history of hereditary cancer of the breast and colon. Cancer 50:360–363PubMedCrossRefGoogle Scholar
  35. 35.
    Fukutomi T, Kobayashi Y, Nanasawa T et al (1993) A clinicopathological analysis of breast cancer in patients with a family history. Surg Today 23:849–854PubMedCrossRefGoogle Scholar
  36. 36.
    Moller P, Evans DG, Reis MM et al (2007) Surveillance for familial breast cancer: Differences in outcome according to BRCA mutation status. Int J Cancer 121:1017–1020PubMedCrossRefGoogle Scholar
  37. 37.
    Maurice A, Evans DG, Shenton A et al (2006) Screening younger women with a family history of breast cancer–does early detection improve outcome? Eur J Cancer 42:1385–1390PubMedCrossRefGoogle Scholar
  38. 38.
    Margolin S, Johansson H, Rutqvist LE et al (2006) Family history, and impact on clinical presentation and prognosis, in a population-based breast cancer cohort from the Stockholm County. Fam Cancer 5:309–321PubMedCrossRefGoogle Scholar
  39. 39.
    Phillips KA (2000) Immunophenotypic and pathologic differences between BRCA1 and BRCA2 hereditary breast cancers. J Clin Oncol 18:107S-112 SGoogle Scholar
  40. 40.
    Armes JE, Trute L, White D et al (1999) Distinct molecular pathogeneses of early-onset breast cancers in BRCA1 and BRCA2 mutation carriers: a population-based study. Cancer Res 59:2011–2017PubMedGoogle Scholar
  41. 41.
    Brekelmans CT, Voogd AC, Botke G et al (1999) Family history of breast cancer and local recurrence after breast-conserving therapy. The Dutch Study Group on Local Recurrence after Breast Conservation (BORST). Eur J Cancer 35:620–626PubMedCrossRefGoogle Scholar
  42. 42.
    Zhong Q, Peng HL, Zhao X et al (2015) Effects of BRCA1- and BRCA2-related mutations on ovarian and breast cancer survival: a meta-analysis. Clin Cancer Res 21:211–220PubMedCrossRefGoogle Scholar
  43. 43.
    Malone KE, Daling JR, Thompson JD et al (1998) BRCA1 mutations and breast cancer in the general population: analyses in women before age 35 years and in women before age 45 years with first-degree family history. JAMA 279:922–929PubMedCrossRefGoogle Scholar
  44. 44.
    Loman N, Bladstrom A, Johannsson O et al (2003) Cancer incidence in relatives of a population-based set of cases of early-onset breast cancer with a known BRCA1 and BRCA2 mutation status. Breast Cancer Res 5:R175–R186PubMedPubMedCentralCrossRefGoogle Scholar
  45. 45.
    Sapkota Y (2014) Germline DNA variations in breast cancer predisposition and prognosis: a systematic review of the literature. Cytogenet Genome Res 144:77–91PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht 2017

Authors and Affiliations

  • Jun-Long Song
    • 1
  • Chuang Chen
    • 1
  • Jing-Ping Yuan
    • 2
  • Sheng-Rong Sun
    • 1
    Email author
  1. 1.Department of Breast and Thyroid SurgeryRenmin Hospital of Wuhan UniversityWuhanPeople’s Republic of China
  2. 2.Department of PathologyRenmin Hospital of Wuhan UniversityWuhanPeople’s Republic of China

Personalised recommendations